JP2001515712A5 - - Google Patents

Download PDF

Info

Publication number
JP2001515712A5
JP2001515712A5 JP2000510770A JP2000510770A JP2001515712A5 JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5 JP 2000510770 A JP2000510770 A JP 2000510770A JP 2000510770 A JP2000510770 A JP 2000510770A JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5
Authority
JP
Japan
Prior art keywords
april
use according
blocking agent
suppressing
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000510770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/019191 external-priority patent/WO1999012965A2/en
Publication of JP2001515712A publication Critical patent/JP2001515712A/ja
Publication of JP2001515712A5 publication Critical patent/JP2001515712A5/ja
Pending legal-status Critical Current

Links

JP2000510770A 1997-09-12 1998-09-11 増殖効果を有する新規タンパク質−ａｐｒｉｌ Pending JP2001515712A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12
US7938498P 1998-03-26 1998-03-26
US60/079,384 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (2)

Publication Number Publication Date
JP2001515712A JP2001515712A (ja) 2001-09-25
JP2001515712A5 true JP2001515712A5 (enExample) 2006-01-05

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510770A Pending JP2001515712A (ja) 1997-09-12 1998-09-11 増殖効果を有する新規タンパク質−ａｐｒｉｌ

Country Status (20)

Country Link
US (3) US20030138884A1 (enExample)
EP (1) EP1027431A2 (enExample)
JP (1) JP2001515712A (enExample)
KR (1) KR100618492B1 (enExample)
CN (1) CN1195849C (enExample)
AU (1) AU759717B2 (enExample)
BR (1) BR9812634A (enExample)
CA (1) CA2303615A1 (enExample)
CZ (1) CZ294615B6 (enExample)
EA (1) EA005411B1 (enExample)
EE (1) EE200000147A (enExample)
HU (1) HUP0004611A3 (enExample)
IL (1) IL134537A0 (enExample)
IS (1) IS5378A (enExample)
NO (1) NO20001242L (enExample)
NZ (1) NZ503850A (enExample)
PL (1) PL339463A1 (enExample)
SK (1) SK3542000A3 (enExample)
TR (1) TR200000669T2 (enExample)
WO (1) WO1999012965A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DK1146892T3 (da) 1999-01-25 2003-11-24 Apoxis Sa BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2001012812A2 (en) * 1999-08-17 2001-02-22 Biogen, Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294949A4 (en) * 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
JP2008505607A (ja) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
AU2006298794B2 (en) * 2005-09-26 2012-05-10 Enzo Life Sciences, Inc. Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
MX2008014365A (es) 2006-05-15 2008-11-27 Ares Trading Sa Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
US8981057B2 (en) * 2010-03-05 2015-03-17 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
KR102407354B1 (ko) * 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
MX358206B (es) * 2013-11-19 2018-08-09 Regeneron Pharma Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
PL3380522T3 (pl) 2015-11-25 2024-03-25 Visterra, Inc. Cząsteczki przeciwciał wobec april i ich zastosowania
CA3199743A1 (en) 2020-10-29 2022-05-05 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
EP4384201A4 (en) 2021-08-11 2025-07-30 Akso Biopharmaceutical Inc METHODS FOR REDUCING THE PRODUCTION OF IGA, IGM AND/OR IGG IMMUNOGLOBULINS USING SBCMA VARIANTS AND THEIR FC FUSION PROTEINS
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
ATE254135T1 (de) * 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Similar Documents

Publication Publication Date Title
JP2001515712A5 (enExample)
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
HK1043313A1 (zh) 用於治疗癌症的多西他赛和rhumab her2
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
CA2214503A1 (en) Method for treating tumors
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
JP2004537500A5 (enExample)
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
CA2032475A1 (en) Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
Zein Interferons in the management of viral hepatitis
CA2091134A1 (en) Therapeutic agent for threatened abortion
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
Corazziari Need of the ideal drug for the treatment of chronic constipation
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
JP2002520292A5 (ja) ヒト成長因子と組み合わせた脈管形成剤としてのコンポーネントｂの使用
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
RU2000103385A (ru) Способ лечения острого панкреотита
CN1053577C (zh) 烧烫散
Molev et al. Efficacy of treating new cases of destructive tuberculosis of the lungs in alcoholism.